FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/06/2026
Voltar para busca
Dado oficial do USPTO
ALLO CHASSIS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ALLO CHASSIS
ST13
US500000079425095Classe
1, 5, 40, 42
Pedido
79425095
Registro
8172902
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
19
Atualização mais recente
18/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 42
Data de depósito
07/04/2025
Data de registro
17/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/03/2026
Última transação
18/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
33
Localização do titular
BE
Examinador
EISNACH, MICHAEL PATRICK
Unidade examinadora
L40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Celyntra Therapeutics SA
Representantes
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Modified cellsin particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefromfor research or scientific purposes; cell culturescell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes; cell culturescryopreserved cells iPS cells other than for medical or veterinary use; Biological preparations for use in cell culturesother than for medical or veterinary purposescell culture agents for use in the biotechnology industry and cell material for use in combination with human cellsparticularly genetically modified iPS or differentiated stem cells
Classe 5
Modified cellsin particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefromfor medical or veterinary use; cell cultures and cell culture systemscryopreserved pluripotent stem cells for medical or veterinary use; genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systemscryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.
Classe 40
Custom manufacturing of iPS derived cellsiPS derived cell therapy and manufacturing processes for othersmanufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cellsmedicinescell therapies and gene edited cell therapies for othersmanufacturing in GMP-based facilities; custom manufacture of cellular therapiesmanufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cells
Classe 42
Research and testing of cell-based productsin particular therapeutic products; researchoptimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom; Scientific researchdesign and development of scientific cell culturecell therapy and gene edited cell therapy; Scientific researchdesign and development of cell culturecell therapy or gene edited cell therapymanufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based productsin the field of cell therapycell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapiesthe associated technologyprocessesdata analytics capabilities for process optimization and quality control
Publicações
Histórico de despachos e eventos da marca no USPTO.
19 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
17/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/01/2026
PUBO
PUBLISHED FOR OPPOSITION
27/01/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/01/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/12/2025
RFNT
REFUSAL PROCESSED BY IB
22/11/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/11/2025
RFRR
REFUSAL PROCESSED BY MPU
05/11/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/09/2025
CNRT
NON-FINAL ACTION WRITTEN
16/09/2025
DOCK
ASSIGNED TO EXAMINER
03/09/2025
MAFR
APPLICATION FILING RECEIPT MAILED
06/06/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/06/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALLO CHASSIS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.